2 transcripts
CRVS
Earnings call transcript
NASDAQ
2024 Q1
6 May 24
mutations, genetic mutations. The fact that we see activity in this very diverse group of lymphomas, of T-cell lymphomas is really, again, consistent
CRVS
Earnings call transcript
NASDAQ
2023 Q4
19 Mar 24
become a pioneer in the research and development of ITK inhibition as a new therapeutic modality to benefit patients with a diverse range of diseases
- Prev
- 1
- Next